AZ’ Farxiga shows 47% reduction in kidney function decline
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
Read More
Tag: SGLT2
US green light for Pfizer/Merck diabetes therapies
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Read More
Mundipharma bags rights to sell Janssen’s Invokana, Vokanamet
Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland.
Read More
UK sees first global launch of AZ’ diabetes combo Qtern
Adults in the UK with type II diabetes have gained a new treatment option to keep blood sugar levels under control with the launch of AstraZeneca’s Qtern in the country.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
